United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by American Century Companies Inc.

American Century Companies Inc. lowered its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 23.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 38,152 shares of the biotechnology company’s stock after selling 11,999 shares during the period. American Century Companies Inc. owned 0.09% of United Therapeutics worth $13,462,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of UTHR. Newbridge Financial Services Group Inc. purchased a new position in shares of United Therapeutics during the fourth quarter worth about $25,000. Millstone Evans Group LLC purchased a new position in United Therapeutics during the 4th quarter worth approximately $67,000. MassMutual Private Wealth & Trust FSB increased its position in United Therapeutics by 31.9% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock worth $85,000 after buying an additional 58 shares during the period. Jones Financial Companies Lllp lifted its stake in United Therapeutics by 678.9% in the fourth quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company’s stock valued at $104,000 after buying an additional 258 shares during the last quarter. Finally, SBI Securities Co. Ltd. acquired a new position in United Therapeutics in the fourth quarter valued at $131,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Insider Activity

In other United Therapeutics news, Director Tommy G. Thompson sold 2,500 shares of the business’s stock in a transaction on Monday, March 24th. The stock was sold at an average price of $318.80, for a total value of $797,000.00. Following the completion of the transaction, the director now directly owns 8,480 shares in the company, valued at approximately $2,703,424. The trade was a 22.77 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Michael Benkowitz sold 10,000 shares of the firm’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $364.91, for a total value of $3,649,100.00. Following the sale, the chief operating officer now owns 2,577 shares in the company, valued at $940,373.07. This trade represents a 79.51 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 72,500 shares of company stock worth $26,134,500 over the last three months. 11.90% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on UTHR shares. HC Wainwright reissued a “buy” rating and set a $425.00 price target on shares of United Therapeutics in a report on Thursday, February 27th. StockNews.com lowered United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 27th. Finally, UBS Group increased their price target on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $388.25.

United Therapeutics Stock Down 0.5 %

NASDAQ:UTHR opened at $306.88 on Wednesday. United Therapeutics Co. has a 52-week low of $225.62 and a 52-week high of $417.82. The stock has a fifty day simple moving average of $337.82 and a 200-day simple moving average of $355.39. The company has a market capitalization of $13.78 billion, a PE ratio of 13.48, a price-to-earnings-growth ratio of 0.97 and a beta of 0.64.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.10 by $0.09. The firm had revenue of $735.90 million during the quarter, compared to the consensus estimate of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same period in the previous year, the firm posted $4.36 EPS. As a group, equities analysts anticipate that United Therapeutics Co. will post 24.48 earnings per share for the current year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.